MRK Stock Analysis — Merck & Co.
Sector: Healthcare
AI Verdict
Merck trades at 16.5x next year's earnings while analysts expect 121.1% EPS growth—this is cheap for the growth on offer if its drug pipeline continues to deliver.
Competitive Moat
Merck's defensibility comes from its portfolio of patent-protected drugs, notably the blockbuster cancer immunotherapy Keytruda, which generates high-margin recurring revenue. Its deep R&D pipeline and global scale create barriers to entry for smaller competitors.
Summary
Analysts expect Merck's earnings to more than double next year, driving a sharp drop in its forward P/E.
Where It Stands
Merck is up 60.09% over the past year, trades at 16.5x next year's earnings versus the healthcare median of 22x, and its RSI of 67.5 signals elevated pullback risk.
Key Metrics
- RSI: 67.5 — Near Overbought
- Trailing P/E: 36.5x
- Forward P/E: 16.5x
- PEG Ratio: 0.30
- Earnings Growth: +1.2%
- Revenue Growth: +0.0%
- Market Cap: $320.0B
- Dividend Yield: 0.03%
- 1-Year Return: 60.09%
- 52-Week High: $130.29
- 52-Week Low: $76.66
Analyst Consensus
25 Buy · 11 Hold · 0 Sell (36 analysts)
Bull Case
With forward EPS growth forecast at 121.1% and a forward P/E of just 16.5x, you're paying a low price for explosive earnings momentum.
Bear Case
RSI at 67.5 means the stock is at risk of a near-term pullback, and if the forward P/E reverts to the sector median of 22x, there's little room for further multiple expansion.
Catalyst to Watch
Watch for clinical trial results or FDA approvals for pipeline drugs, as positive outcomes could further support the earnings surge analysts expect.